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Possible role of cytokines on the bone mineral loss in idiopathic
hypercalciuria. Decreased bone mass has been reported in patients with
idiopathic hypercalciuria. Previous studies, using bioassays, have sug-
gested a role of interleukin-1 (IL-i), in the decreased bone mineral density
(BMD) of fasting hypercalciuria. The present study was designed to
determine which IL-i fraction (a or 13) correlates with bone resorp-
tion and whether other known bone resorting cytokines like inter-
leukin-6 (IL-6) and tumor necrosis factor a (TNF-a) may play a role in
this process. Cytokines production was determined by quantitative and
specific analysis, enzyme-linked immunosorbent assay (ELISA) and re-
verse transcriptase polymerase chain reaction (RT-PCR). Dual-energy
X-ray absorptiometry and cytokine production by unstimulated and
lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells(PBMCs) were determined in a group of 29 patients with recurrent
nephrolithiasis (17 hypercalciurics and 12 normocalciurics), and 12
healthy controls. The hypercalciuric subjects showed lower vertebral BMD
than the normocalciuric or normal controls. There was no difference in
spinal or femoral BMD between absorptive or fasting hypercalciurics. A
significant negative correlation existed between urinary calcium excretion
and vertebral BMD (r =
—0.55, P < 0.01). Basal IL-la production
correlated with vertebral BMD (r =
—0.45, P < 0.02). This correlation was
not seen with lL-1j3, IL-6 or TNF-a production. LPS-induced IL-6 and
TNF-a production were enhanced in the hypercalciuric patients, when
compared to normocalciurics or controls. Control and normocalciuric
subjects showed minimal amounts of IL-la mRNA. In contrast, hypercal-
ciuric patients showed a significant increase of spontaneous IL-la mRNA
transcription. These results suggest that different cytokines could be
involved in the bone resorption process observed in hypercalciuria.
Nephrolithiasis is a common clinical disorder affecting 1 to 5%
of the general population with an annual incidence of 0.1 to 0.3%
[1, 2]. In certain areas of the world, the incidence appears to be
much higher [3, 4]. A recent report on demographic and geo-
graphic variability of kidney stones in the United States showed an
increased prevalence with age until age 70, and a higher incidence
in men, and in whites over blacks [5].
Stone formation usually results from an imbalance in the urine
between oversaturation of factors that promote crystallization,
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and those that inhibit crystal formation and growth [6, 7]. It is
generally agreed that the oversaturation of urine with calcium is
one of the most important risk factors for calcium nephrolithiasis.
It promotes stone formation by different mechanisms, including
saturation of urine with respect to calcium oxalate and calcium
phosphate [8]. In addition, calcium binds to inhibitors of crystal-
lization such as citrate and glycosaminoglycans, thus reducing
their inhibitory activity [9].
Idiopathic hypercalciuria accounts for almost half of the pa-
tients in most series. This metabolic alteration, is defined as the 24
hours urinary calcium excretion of more than 4 mg/kg/day or in
excess of 140 mg of calcium per gram of creatinine in two
consecutive collections [10], in the absence of different systemic
diseases that cause normocalcemic hypercalciuria [11].
Decreased bone mineral density has been reported in patients
with nephrolithiasis by different techniques including photon
absorptiometry of the distal radius [12, 13] and lumbar spine [14],
radiological evaluation of the proximal radial shaft [15], and in
vivo neutron activation analysis and whole body counting [16].
Other studies have demonstrated decreased bone mineral content
in patients with fasting or renal hypercalciuria, but normal values
in those with absorptive hypercalciuria [17, 18].
Studies by Pacifici et al demonstrated that mononuclear cells
from patients with fasting hypercalciuria had an increased spon-
taneous production of interleukin 1 (IL-i) [19], a potent stimula-
tor of bone resorption [20], as determined by bioassay. This
finding correlated with the bone mineral content measured at the
lumbar spine by computed tomography, and was not present in
patients with absorptive hypercalciuria. However, this study was
performed in fasting hypercalciuric patients with a mean age of
46.8 years, and thus, potentially included some postmenopausal
women in whom decreased bone mineral content has been
previously demonstrated [21]. Previous studies have shown the
participation of other cytokines, such as interleukin-6 (IL-6) and
tumor necrosis factor-a (TNF-a) in the modulation of bone
remodeling [22]. Therefore, in the present study we have exam-
ined the correlation between bone mineral content in kidney
stone formers that included men and premenopausal women, and
the in vitro production of these cytokines by peripheral blood
mononuclear cells (PBMC5), as measured by quantitative and
specific analysis as the enzyme-linked immunosorbent assays
(ELISA), and reverse transcriptase polymerase chain reaction
(RT-PCR).
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Table 1. Clinical and biochemical characteristics of controls and stone
formers with normocalciuria or hypercalciuria
Control
(N = 12)
Normocalciuria
(N = 12)
Hypercalciuria(N = 17)
Sex ratio FIM 8/4 8/4 13/4
Age years 33.7 3.7 35.2 4.9 32.3 4.3
Height cm 163.9 1.6 164.1 1.4 162.3 1.9
Weight kg 71.3 4.9 65.3 6.7 68.2 6.4
Urinaiy calcium 1.59 1.3 1.45 1.4 6.1 1.5°
mg/kg/day
Serum calcium 9.51 0.11 9.48 0.10 9.49 0.12
mg/di
Serum creatinine 1.2 0.08 1.12 0.11 1.3 0.12
mg/di
PTH pg/mI 29.1 3.1 27 2.3 33.4 4.5
Values are means SEM.
a P < 0.001 vs. controls and normocalciurics
Methods
Patients
We examined 29 patients with recurrent renal stones, and 12
healthy normal controls (Table 1). The patients were recruited
from the Kidney Stone Clinic at the University Hospital of
Caracas. All patients had at least one stone passage during the 12
months preceding the study. Except for hypercalciuria, none of
the patients showed evidence of diseases that could affect calcium
excretion, bone metabolism or monocyte function. We excluded
from the study postmenopausal women or subjects that were
treated with estrogen, progesterone, corticosteroids, anticonvulsi-
vants, fluoride, biphosphonates, calcitonin, calcium replacement,
antacids, antiinflammatory or cytotoxic drugs and vitamin D.
None of the patients were taking diuretics or any specific treat-
ment for hypercalciuria. An informed consent was obtained in all
subjects.
The subjects were instructed to ingest at least 900 mg of calcium
in their diets for at least two weeks before starting the study. After
this period of equilibration, two consecutive 24-hour urine and
blood samples were collected. The urine samples were assayed for
levels of calcium and creatinine, and the blood samples for
calcium, creatinine and immunoreactive PTH. After these sam-
ples were collected, a one week period on a low calcium diet of 2
mg of calcium per kg of body wt was instituted. Then, a standard
calcium tolerance test was performed [23]. Briefly, after a twelve-
hour overnight fast a two-hour urine sample was collected. One
gram of elemental calcium in a mixture of milk and calcium
gluconate (NeoCalgiucon) was administered over a 10 minute
period. Two hours later, a second two-hour urine sample was
obtained. Fasting and midpoint blood samples and urines were
analyzed for calcium and creatinine.
Bone density measurement
Each participant had a bone mineral measurement of the whole
body, spine and the femur. The neck of the femur and Ward's
triangle were recorded separately. Bone mineral measurements
were done by the dual X-ray absorptiometiy (DEXA) technique
with a Lunar DPX-L machine (Lunar Corporation, Madison, WI,
USA). The bone mineral content for every skeletal location was
expressed in grams and divided by the projected area of the bone
to derive the bone mineral area density (BMD) in grams per
square centimeter. In order to compare patients of different ages,
we used the score Z, which compares the value of every patient to
their same age and gender normal control population.
The precision error in our laboratory was 0.7% for the whole
body, 1% for antero-posterior spine, 0.7% for the femoral neck
and 3.2% for the Ward's triangle.
Laboratory methods
Monocyte cultures. Blood was drawn from patients and controls
into heparinized tubes. PBMCs were isolated after Ficoll-
Hypaque density gradients (Sigma Chemical Co., St. Louis, MO,
USA). Cells were removed from the interface and washed twice
with RPMI-1640 and resuspended in 10 ml medium supple-
mented with 10% heat-inactivated fetal bovine serum (complete
medium). This preparation was allowed to adhere for 45 minutes
into a plastic Petri dish at 37°C in an atmosphere of 5% CO2. The
non-adherent cells were removed from the plate, and the adher-
ent cells were washed twice to remove any remaining non-
adherent cells. The adherent cell population was then incubated
in complete medium at a concentration of 1 X 106 cells/ml during
48 hours. The supernatant fractions were then collected and
passed through 0.22 tm Millipore filters and stored at —20°C
until assayed. The adherent cell population contained more than
95% monocytes, as assessed for the monocyte-macrophage-spe-
cific enzyme alpha naphtyl acetate esterase with a commercial kit
(Sigma Chemical Co.).
Lipopolysaccharide (LPS)-induced cytokine production by ad-
herent cells was also studied in parallel cultures containing a
predetermined optimal concentration of LPS (Escherichia coli
0111:B4, Sigma Chemical Co.). Cultures were stopped and cell
supernatants were collected and stored frozen at —70°C until
analysis.
Cytokine assays, Cell supernatants were tested for IL-la, IL-113,
IL-6 and, TNF-a with a sensitive enzyme-linked immunosorbent
assay (ELISA), (R&D Systems, Minneapolis, MN, USA). The
minimum detectable dose, using the IL-la, IL-113, IL-6 and
TNF-a assays, were 0.3, 0.3, 0.35 and 4.8 pg/mi, respectively.
RT-PCR. Total RNA was extracted as previously described by
Chomczynski and Facci [24] In brief, 500 pi of lysis solution were
added to 1 x 106 frozen cell pellets. The lysis solution contained
4 M guanidine-thiocyanate (Fluka AG, Buchs, Switzerland), 25
m Na citrate (pH 7.0), 0.5% sarcosyl (Fluka) and 100 mrvt
2-mercaptoethanol (Sigma Chemical Co.). Cell lysates were se-
quentially added with 500 .d 2 M Na acetate, 500 il water-
saturated phenol (Fluka) and 100 .il chioroform-isoamyl alcohol
(24:1) and thoroughly mixed by inversion after the addition of
each reagent. The final suspension was shaken for 10 seconds and
chilled on ice for 15 minutes. Samples were spun at 10,000 g at +
4°C. The aqueous phase was transferred to a clean Eppendorf
tube and RNA was precipitated in an equal volume of isopropanol
at —20°C for 60 minutes. Precipitates were washed twice in 95%
ethanol. Air dried pellets were resuspended in 20 p.! RNAase-free
water.
First strand eDNA synthesis was performed at 43°C for 90
minutes in a final volume of 20 p.! containing 0.6 p.1 RNAsin (40
U/p.l, Promega, Madison, WI, USA), 4 p.1 5 X buffer (BRL,
Gaithersburg, MD, USA), 2 p.! dNTP 10 mM (Promega), 2 p.!
oligo-dT (0.5 p.g/m!; Pharmacia) and 0.7 p.! AMV reverse tran-
scriptase, 7.5 U/mi (Promega). eDNA from each sample was
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Fig. 1. Bone mineral density determined at the lumbar spine (L2-L4), in
normal control subjects (N = 12) and normocalciuric (N = 12) and
hypercalciuric (N 17) kidney stone formers. Bone mineral density is
expressed as g/cm2.
synthesized in one tube and then divided into separate tubes for
the PCR.
Twenty microliters of PCR mix were added to 4 j.d of first
strand eDNA. PCR mix contained 2.5 j.tl 10 X buffer (100 mM
Tris-HC1, 500mM KCI, 0.1% wt/vol gelatin, pH 8.3), 1.5 .tl 25 mM
MgCI2, 2.5 d dNTP 2 mrvi (Promega), 14 .d sterile water and 0.5
j.l of Taq polymerase 5 U/mI (Promega). eDNA was then
amplified, using a PTC-100 thermal cycler (M.J. Research, Inc.)
for 35 cycles. The temperature profile used was: 94°C for one
minute for denaturation, 60°C one minute for annealing, 72°C one
minute for primer extension. The efficiency of reversed transcrip-
tion and eDNA amplification was evaluated using human f3 actin
as an internal control. Cytokine specific primers for IL-la and
human actin were obtained from Clontech (Palo Alto, CA,
USA).
PCR products were separated on ethidium bromide-stained
1.6% agarose gel (Sigma Chemical Co.), and the intensity of
bands read in an imaging densitometer model GS-670 (Bio-Rad,
Hercules, CA, USA).
Biochemical assays. Blood and urinary calcium and creatinine
were determined by standard atomic absorptiometry and photo-
metric methods, Intact PTH was determined by an immunoradio-
metric assay (Nichols Institute Diagnostics, San Juan Capistrano,
CA, USA).
Hypercalciuria was defined as a calcium excretion higher than 4
mg/kg of body wt or 140 mg/g of creatinine.
Statistical analysis
Results are presented as mean SCM. Comparisons between
two groups of data were done by Student's t-test for unpaired
observations (two-tailed). Comparison between two variables
were done by linear regression analysis. A P value of < 0.05 was
considered significant.
Table 2. Basal and LPS-stimulated cytokine production by peripheral
blood mononuclear cells in controls and stone formers with
normocalciuria or hypercalciuria
LPS-
Basal stimulated
Control (N = 12)
IL-la 87.7 25.3 157.1 101.3
IL-6 10.1 4.5 11.6 2.1
TNF-a 759.7 178.5 1,493 299
Normocalciuria (N = 12)
IL-la 115 70 253 61
IL-6 11.5±5.5 11.7±5
TNF-a 1,520 343 1,910 465
Hypercalciuria (N = 17)
IL-la 265.1 92.1° 680.3 l39l
IL-6 16.3 6.2 19.3 43c
TNF-a 1,739 343 2,976 417°
Values are means SEM.
ap < 0.01 vs. basal IL-Ia in control and normocalciuric subjects
bp < 0.01 vs. LPS-stimulated IL-ia in control and normocalciuric
subjects
p < 0.01 vs. LPS-stimulated IL-6 in control subjects
d P < 0.05 vs. LPS-stimulated IL-6 in normocalciuric subjects
P < 0.01 vs. LPS-stimulated TNF-a in control and normocalciuric
subjects
Results
Of 29 kidney stone formers recruited, 17 showed evidence of
hypercalciuria and 12 had normal urinary calcium excretion, As
illustrated in Figure 1, the hypercalciuric patients showed lower
vertebral bone mineral content when compared to the normocal-
dune stone formers (P < 0.02) or the control subjects (P < 0.001).
Similar results were observed at the Ward's triangle, another
measure of trabecular bone mineral content. No differences
between hypercalciuric and normocalciuric patients or control
subjects were observed in areas such as the femoral neck, where
cortical bone predominates.
When hypercalciuric patients were subclassified, according to
the Pak's acute calcium absorption test, in fasting (N = 7) or
absorptive (N = 10) hypercalciurics, no significant differences
were observed in bone mineral content determined at the spine,
femur or total body. All the subjects with fasting hypercalciuria
demonstrated persistently elevated urinary calcium excretion after
a week on the low calcium diet. On the contrary, all the patients
except one with absorptive hypercalciuria reduced their urinary
calcium excretion significantly, after the week on dietary calcium
restriction.
A significant inverse correlation was observed between urinary
calcium excretion and the Z score of spinal bone mineral content
in the stone forming patients (r =
—0.55, P < 0.01). No
correlation was observed between cortical bone mineral content,
determined at the femoral neck, and urinary calcium excretion.
Table 2 shows spontaneous and LPS-stimulated cytokine pro-
duction by PBMCs obtained from patients and control subjects. In
vitro production of iL-la in unstimulated cultures was higher in
hypercalciuric stone formers than in normocalciuric or healthy
controls. Spontaneous IL-6 and TNF-a production was similar in
all groups. The increased spontaneous production of IL-la in vitro
correlated inversely with the Z score of the lumbar spine mineral
content (r =
—0.45, P < 0.02; Fig. 2). In contrast, no correlation
was found between IL-la production and the Z score of bone
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in unstimulated PBMCs obtained from hypercalciuric patients is
increased as compared to normal subjects or normocalciuric stone
formers.
Several studies using different techniques have shown de-
creased bone mineral density in patients with nephrolithiasis and
hypercalciuria [12—16]. It has been suggested that an increased
bone turnover may account for the hypercalciuria in these patients
[251. In another study, while radial (or cortical) bone density was
diminished in patients with renal hypercalciuria or primary hyper-
parathyroidism, it remained normal in those with absorptive
hypercalciuria [17]. This same group reported some years later,
using dual-energy X-ray absorptiometry, that patients with both,
absorptive and fasting hypercalciuria with normal PTH (non-PTH
mediated resorptive hypercalciuria) had decreased spinal bone
density. Radial bone density in both groups was normal [26].
Another study demonstrated that patients with persistent hyper-
calciuria after a low calcium diet showed decreased vertebral
mineral density by quantitative computed tomography, whereas
those in whom hypercalciuria was controlled by calcium restric-
tion showed normal vertebral mineral density values [27]. In the
present study we have found that bone mass is similarly decreased
in fasting or absorptive hypercalciuric patients, suggesting that in
both forms of hypercalciuria there is a long-term negative calcium
balance, which could result in a progressive loss of bone mass.
This similarity between bone mass in patients with fasting and
absorptive hypercalciuria are in agreement with the unifying
hypothesis advanced by Coe and Parks [28], which suggest that all
patients with idiopathic hypercalciuria have a similar pathophys-
iological derangement and could display a spectrum of behavior
ranging from predominantly absorptive to pure fasting (renal)
hypercalciuria [11].
Results of bone histomorphometric studies in hypercalciuric
patients have reported increased osteoclastic resorption accom-
panied by decreased osteoblastic surfaces [29—31]. However,
Malluche et al have found normal or even decreased bone
resorption [32].
At the present time the cellular mechanisms responsible for the
apparent increase in bone resorption are not clear. Recent studies
have shown a correlation between decreased bone mass and the
increased production of IL-i by mononuclear cells in postmeno-
pausal osteoporosis [33] and hypercalciuria [19], suggesting a role
of cytokines in the pathogenesis of bone resorption in these
patients. Therefore, in order to further investigate a possible
cause-effect relationship between cytokine production and bone
mass loss in hypercalciuria in addition to IL-i, we extended our
studies to other cytokines that have shown to be involved in bone
resorption [22, 34].
We found a correlation between basal production of IL-la, but
not IL-113, and decreased trabecular bone mineral. In addition,
the production of IL-6 and TNF-a was elevated in LPS-stimulated
PBMCs obtained from hypercalciuric patients, but not in normo-
calciuric stone formers or normal subjects. These eytokines have
shown to play a role in bone remodeling. Indeed, IL-6 is known to
induce osteoclast formation and bone resorption [22], and IL-i-a
and TNF-a may induce bone resorption through stimulation of
IL-6 as has been suggested previously [35]. Therefore, it is
possible that in idiopathic hypercalciuria the initial event could be
an increase in the rate of IL-la production which may lead to
stimulation of IL-6, resulting in enhanced bone resorption.
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Fig. 2. Relationship between in Vitro IL-la production in unstimulated
cultured adherent cells and the Z score of vertebral mineral density (L2-L4),
in kiidney stone formers. Z score represents the comparison of the bone
mineral density with age and gender matched normal controls; r repre-
sents the linear regression analysis correlation coefficient. r =
—0.45;P <
0.02.
evaluated at the femoral neck. There was no correlation between
unstimulated IL-1f3, IL-6 or TNF-a production in vitro and
vertebral or femoral bone mineral content.
We then evaluated LPS-induced cytokine production by PB-
MCs. There was a significant enhancement in the observed IL-la,
IL-6, and TNF-a production in the hypercalciuric subjects com-
pared to normocalciuric stone formers or control subjects (Table
2). The afore mentioned experiments suggest enhanced produc-
tion of cytokines involved in bone resorption in hypercalciuric
stone formers.
To examine the mechanism of enhanced IL-ia production at
the molecular level, we measured transcription of cytokine
mRNA by RT-PCR. As shown in Figure 3, the expression of
IL-la mRNA in unstimulated PBMCs obtained from hypercalci-
uric patients was increased, when compared to normocalciuric or
control subjects. By densitometric reading the hypercalciurics
showed a significantly higher band density (7.23 0.21 U) when
compared to the normocalciuric stone formers (3.67 0.06 U) or
the normal control subjects (3.27 0.08 U).
Hypercalciuric men and women behave similarly in terms of
their bone mineral status, and cytokine production, either by basal
or stimulated cultures of PBMCs or by RT-PCR.
Our results demonstrate that patients with idiopathic hypercal-
ciuria have decreased bone mineral content when compared to
normocalciuric or normal control subjects. This decrease in bone
mass correlates with the degree of hypercalciuria and with the
basal production of IL-la by PBMCs in vitro. Further, stimulation
of PBMCs from hypercalciuric patients by LPS resulted in an
enhanced production of IL-6 and TNF-a.
Finally, we have also found that the expression of IL-la mRNA
Discussion
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Fig. 3. Gel electrophoresis of IL-Ia (A) and
human I actin (B) cDNA, amplified by RT-PCR.
Total RNA was extracted from unstimulated
PBMCs obtained from normal controls (C) and
from normocalciuric (N) and hypercalciuric (H)
stone formers. The positive control is
represented as +.
The possible relationship between the increased cytokine pro-
duction and 1,25(OH)2D is not clear at the present time. Previous
studies have shown that most patients with idiopathic hypercalci-
uria have normal or elevated 1,25(OH)2D levels [11]. Although
theoretically an increased in bone resorption could lead to
inhibition of 1,25(OH)2D, recent evidence indicates that this
hormone by itself may induce increased IL-i receptor expression
and TL-6 production by osteoblasts in a dose dependent manner
[36].
Unstimulated PBMCs from healthy subjects contain very little
mRNA for IL-i, as assessed by Northern blot analysis [371 or PCR
[381. Nevertheless, these cells could be easily stimulated to
produce the polypeptide cytokines in vitro. Cytokines such as IL-i
and TNF-a are involved in the pathogenesis of many diseases
including sepsis, rheumatoid arthritis, Kawasaki syndrome and
chronic hemodialysis [39, 40]. The mechanism of increased IL-la
by mononuclear cells in our patients with idiopathic hypercalci-
uria remains unclear, since determination of IL-la protein levels
either by bioassay or immunoradiometric assay cannot differenti-
ate between an increase in de novo synthesis, augmented secretion
or decreased degradation of this cytokine. Our results demon-
strating increased production of IL-icr mRNA suggest that the
increased production of IL-la may be the result of increased
transcription (transcriptional level) or enhanced stabilization of
IL-la mRNA (post-transcriptional level).
Cytokines could play an important role in bone resorption in
different ways. First, by a direct effect on osteoclast-mediated
bone resorption, either by direct activation or by cell recruitment
[41]. Alternatively, some cytokines, particularly IL-i could stimu-
late prostaglandin E (PGE) release [42, 43], with a known
bone-resorption potential. There is also evidence that patients
with idiopathic hypercalciuria have increased urinary excretion of
PGE [441.
Whether the decrease in bone mineral mass constitutes the
primary event responsible for the hypercalciuria, or its conse-
quence, dietary calcium restriction in patients with hypercalciuria
could have deleterious effects on bone metabolism, as has been
shown in experimental animals [51• Furthermore, Curhan et al
[46] have shown that the incidence of symptomatic kidney stones
during a follow-up of four years was lower by almost 50% among
the men with the highest calcium intake. Thus, dietary restriction
of calcium not only fails to decrease the incidence of subsequent
calcium oxalate stones, but possibly further aggravates bone
mineral loss. The latter seems particularly of concern when
treating children with active bone mineral accretion, and women
who eventually will face menopause. We and others have recently
analyzed the bone mineral content of hypercalciuric children and
found lower trabecular bone mineral content at the lumbar spine
than age and height matched controls [47, 48]. The potential
impact of these findings on final peak bone mass, a major
determinant of adult bone mass [49], needs to be further evalu-
ated. Thus, it is possible that the lower peak bone mass reached
during the adolescent years could represent another potential
factor responsible for the final lower bone mass observed in adult
hypercalciuric subjects.
From this discussion we can conclude that even though the
pathophysiology of hypercalciuria cannot be explained by one
single mechanism or theory, PBMCs and very likely bone cells and
bone cell precursors, may play a central role in the chain of events
leading to hypercalciuria.
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